New trial aims to stop leukemia relapse after transplant
NCT ID NCT03821610
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial compares two different chemotherapy and radiation regimens given before a stem cell transplant for adults aged 40-70 with acute lymphoblastic leukemia (ALL) in remission. The goal is to see if a stronger regimen (using total body irradiation and cyclophosphamide) can reduce the chance of the cancer returning without increasing the risk of dying from the transplant. About 242 patients will be randomly assigned to one of the two regimens and followed for at least 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fludarabine, Melphalan, Alemtuzumab, Cyclophosphamide, Mesna, Total Body Irradiation (8Gy)
- What this could lead to
- If successful, this could identify a better pre-transplant regimen that reduces the chance of leukemia returning after a stem cell transplant.
- What could go wrong
- This is a Phase 2 trial, so results are still preliminary. The stronger regimen may increase side effects or transplant-related deaths, and it may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Barts Health Nhs Trust
London, E11BB, United Kingdom
-
Cambridge University Hospitals Nhs Foundation Trust
Cambridge, CB20QQ, United Kingdom
-
Cardiff and Vale University Health Board
Cardiff, CF144XW, United Kingdom
-
Central Manchester University Hospitals Nhs Foundation Trust
Manchester, United Kingdom
-
Heart of England Nhs Foundation Trust
Birmingham, B95ST, United Kingdom
-
Imperial College Healthcare Nhs Trust
London, W21NY, United Kingdom
-
Kings College Hospital
London, SE5 9RS, United Kingdom
-
Leeds Teaching Hospitals Nhs Trust
Leeds, LS9 7TF, United Kingdom
-
NHS Greater Glasgow and Clyde
Glasgow, G12 0YN, United Kingdom
-
Nottingham University Hospitals Nhs Trust
Nottingham, NG72UH, United Kingdom
-
Oxford University Hospitals Nhs Foundation Trust
Oxford, OX3 9DU, United Kingdom
-
Plymouth Hospitals Nhs Trust
Plymouth, PL68DH, United Kingdom
-
Sheffield Teaching Hospitals Nhs Foundation Trust
Sheffield, S57AU, United Kingdom
-
The Christie Nhs Foundation Trust
Manchester, M204BX, United Kingdom
-
The Clatterbridge Cancer Centre Nhs Foundation Trust
Liverpool, CH634JY, United Kingdom
-
The Newcastle Upon Tyne Hospitals Nhs Foundation Trust
Newcastle, United Kingdom
-
The Royal Marsden Nhs Foundation Trust
London, SW3 6JJ, United Kingdom
-
University College London Hospitals Nhs Foundation Trust
London, NW12PG, United Kingdom
-
University Hospital Southampton Nhs Foundation Trust
Southampton, SO16 6YD, United Kingdom
-
University Hospitals Birmingham Nhs Foundation Trust
Birmingham, United Kingdom
-
University Hospitals Bristol Nhs Foundation Trust
Bristol, BS13NU, United Kingdom
-
University Hospitals of Leicester Nhs Trust
Leicester, LE15WW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Can a smart drug missile tame Hard-to-Treat leukemia?